Tocira 400mg Infusion

Introduction

Tocira is a prescription medication that contains the active ingredient Tocilizumab. It is available in the form of an infusion and is commonly used to treat certain inflammatory conditions.

Uses

Tocira is primarily prescribed to manage conditions such as rheumatoid arthritis and giant cell arteritis in adults. It is also used in the treatment of certain types of juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis in children.

Dosage and Administration

The dosage of Tocira is determined by your healthcare provider based on your specific condition and medical history. It is usually administered through an intravenous infusion, which is slowly injected into a vein over a period of time. The exact dosing schedule and duration of treatment will be determined by your healthcare professional.

Mechanism of Action

Tocilizumab, the active ingredient in Tocira, works by targeting a specific protein called interleukin-6 (IL-6). IL-6 is involved in the inflammatory process and plays a role in certain autoimmune diseases. By blocking the action of IL-6, tocilizumab helps reduce inflammation and alleviate symptoms associated with conditions like rheumatoid arthritis and giant cell arteritis.

Side Effects

Common side effects may include headache, nausea, diarrhea, and upper respiratory tract infections. These side effects are usually mild and transient.

However, there are also some serious side effects that may occur. These can include serious infections, allergic reactions, liver problems, and changes in blood cholesterol levels. Seek medical attention if you experience severe or persistent side effects.

Drug Interactions

Tocira may interact with other medications, including certain immunosuppressive drugs and vaccines. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal supplements, to minimize the risk of potential interactions. Your healthcare provider will closely monitor your condition and adjust your treatment plan accordingly.

Precautions

Before using Tocira, inform your healthcare provider about any medical conditions you have, especially if you have a history of infections, liver problems, or high cholesterol. Disclose any medications, supplements, or vaccines you are currently taking.

Tocira is not recommended for use during pregnancy or while breastfeeding, as its safety in these situations has not been established. Discuss the potential risks and benefits with your healthcare provider.

Storage

Patient Tips

• attend all scheduled appointments with your healthcare provider to monitor your response to Tocira and to address any concerns or questions you may have.
• If you experience any new or worsening symptoms while using Tocira, such as persistent infections, severe allergic reactions, or changes in your overall health, seek medical attention promptly.
• Follow your healthcare provider’s instructions regarding any necessary laboratory tests or monitoring while using Tocira.
• If you have any questions or concerns about the medication, its administration, or potential side effects, do not hesitate to reach out to your healthcare provider for clarification and guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• RoActemra 162 mg Solution for Injection in Pre-Filled Pen (Health Professionals SmPC) Available at:
• Tocilizumab (Drugs.com) [Accessed 16 Jun. 2024] (online) Available at:
• tocilizumab solution (RX) [Accessed 0 Jun. 2024] (online) Available at:
• Tocilizumab Injection (MedlinePlus) [Accessed 30 Jun. 2024] (online) Available at:
• Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849. [Accessed 1 Jun. 2024] Available at: